NASDAQ · EOLS
Evolus, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EOLS: Nov 04, 2026
Evolus, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.2.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.14 | 2 |
| Dec 2026 | $0.02 | $0.06 | $-0.02 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · RTTNews · MarketBeat- Zacks · Oct 8, 1:02 PM EDTUTMD Trades at a Premium to the Industry: How to Play the Stock?Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
- BNK Invest · Sep 28, 6:44 AM EDTAdd Up The Pieces: IHE Could Be Worth $116Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
- RTTNews · Sep 7, 10:28 PM EDTBiotech Stocks At 52-Week Highs – PDEX +18% On FY'26 Results, ODTX +8%, EOLS, BFRI, DRTS(RTTNews) – The following biotech stocks reached a 52-week high on September 4, 2026, as various companies reported financial results and anticipated near-term clinical trial readouts.
- RTTNews · Sep 1, 3:46 AM EDTBiotech Stocks At 52-Week Highs – RNXT +15%, EOLS, CRNX, APGE(RTTNews) – The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.
- RTTNews · Sep 1, 1:59 AM EDTTelix Appoints Gill As Board Chairman(RTTNews) – Telix Pharmaceuticals Limited (TLX), a commercial-stage biopharmaceutical company, on Tuesday announced the appointment of David Gill as Chair of the Board, effective immediately.
- Zacks · Aug 27, 9:55 AM EDTWall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a BetThe mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Aug 11, 9:55 AM EDTWall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- MarketBeat · Aug 5, 9:03 PM EDTEvolus Q2 Earnings Call HighlightsEvolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding internationa
- Zacks · Aug 5, 8:35 PM EDTEvolus, Inc. (EOLS) Reports Break-Even Earnings for Q2Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 28, 6:00 PM EDTJushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue EstimatesJushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 7, 10:39 AM EDTResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- BNK Invest · Jul 1, 3:34 PM EDTNotable Wednesday Option Activity: EOLS, PRCH, ZSLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Evolus Inc (Symbol: EOLS), where a total volume of 4,005 contracts has been traded thus far today, a contract volume which is representative of approximately 400
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Evolus, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.